Compound Detail
CHEMBL1963681
AVANAFIL 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL1963681 |
| Name | AVANAFIL |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | WEAJZXNPAWBCOA-INIZCTEOSA-N |
| Therapeutic | ✓ Yes |
5
Targets
43
Activities
2
Assay Types
0
PK Parameters
20
Publications
5
Known Names
3
Indications
1
Mechanisms
Molecular Properties
484.0
MW (Da)
2.43
ALogP
9
HBA
3
HBD
125.4
PSA (Ų)
0.42
QED
0
Ro5 Violations
9
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2011 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Phosphodiesterase 5A inhibitor | INHIBITOR | cGMP-specific 3',5'-cyclic phosphodiesterase | ✓ | ✓ |
Indications
Erectile Dysfunction Erectile Dysfunction Kidney Diseases
ATC Classification
G04BE10
avanafil
Level 1: GENITO URINARY SYSTEM AND SEX HORMONES
Level 2: UROLOGICALS
Activity Summary
IC50 42 meas. best 8.28
Ki 1 meas. best 8.3
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| cGMP-specific 3',5'-cyclic phosphodiesterase CHEMBL1827 | Ki | 8.3 | 8.3 | 5.0 | 1 |
| cGMP-specific 3',5'-cyclic phosphodiesterase CHEMBL2304402 | IC50 | 8.28 | 8.28 | 5.2 | 1 |
| cGMP-specific 3',5'-cyclic phosphodiesterase CHEMBL1827 | IC50 | 8.15 | 7.5988 | 7.0 | 26 |
| NCI-H1299 CHEMBL612255 | IC50 | 5.15 | 4.985 | 7100.0 | 2 |
| NCI-H661 CHEMBL1075544 | IC50 | 5.09 | 4.6633 | 8200.0 | 3 |
| A549 CHEMBL392 | IC50 | 4.91 | 4.77 | 12300.0 | 2 |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 39149110 | 10.1039/d4md00364k | A549 | 17 |
| 39149110 | 10.1039/d4md00364k | NCI-H1299 | 14 |
| 39149110 | 10.1039/d4md00364k | NCI-H661 | 13 |
| 25455484 | 10.1016/j.bmcl.2014.10.008 | Unchecked | 11 |
| 32663396 | 10.1021/acs.jmedchem.0c00853 | cGMP-specific 3',5'-cyclic phosphodiesterase | 10 |
| 39149110 | 10.1039/d4md00364k | Unchecked | 3 |
| 32631538 | 10.1016/j.bmcl.2020.127337 | cGMP-specific 3',5'-cyclic phosphodiesterase | 2 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 2 |
| - | 10.6019/CHEMBL4495564 | Replicase polyprotein 1ab | 1 |
| - | 10.1101/2020.04.21.054387 | SARS-CoV-2 | 1 |
| 25455484 | 10.1016/j.bmcl.2014.10.008 | cGMP-specific 3',5'-cyclic phosphodiesterase | 1 |
| - | 10.1101/2020.04.03.023846 | SARS-CoV-2 | 1 |
| 30245400 | 10.1016/j.ejmech.2018.09.028 | cGMP-specific 3',5'-cyclic phosphodiesterase | 1 |
| 30245400 | 10.1016/j.ejmech.2018.09.028 | Unchecked | 1 |
| 25455484 | 10.1016/j.bmcl.2014.10.008 | Corpus cavernosum | 1 |
| - | 10.6019/CHEMBL5724796 | Casein kinase I isoform delta | 1 |
| - | 10.6019/CHEMBL5724796 | Cyclin-dependent kinase 2 | 1 |
| - | 10.6019/CHEMBL5724796 | Glycogen synthase kinase-3 beta | 1 |
| - | 10.6019/CHEMBL5724796 | Mitogen-activated protein kinase 1 | 1 |
| - | 10.6019/CHEMBL5724796 | Aurora kinase A | 1 |
Data from ChEMBL 36 via Core Engine